All In Biotech

Drug Trial Radar · NCT04318743

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

A Bridging Trial to Compare the Pharmacokinetics of Glepaglutide (ZP1848) After Single Subcutaneous Adminstration by Vial/Syringe and by Autoinjector in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Mar 4, 2020

Primary completion

Jun 10, 2021

Study completion Jun 10, 2021

Sponsor

Lead sponsor
Zealand PharmaIndustry
Sponsor type
Industry
First posted
Mar 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 54 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, single center, 2-treatment, 3-period, 3-sequence reference-replicated, crossover trial in healthy subjects to compare the PK of glepaglutide (ZP1848) after a single SC administration by vial/syringe and by autoinjector.

Conditions

  • Healthy

Interventions

  • GlepaglutideDrug

    GLP-2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic VariablesTime frame: From time zero to the last time point with a measurable concentration
  2. Pharmacokinetic VariablesTime frame: from time zero to the last time point with a measurable concentration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences- Location Martini

    Groningen, NZ, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.